Barclays PLC Buys 31,331 Shares of FibroBiologics, Inc. (NASDAQ:FBLG)

Barclays PLC raised its holdings in FibroBiologics, Inc. (NASDAQ:FBLG) by 363.2% in the third quarter, according to the company in its most recent disclosure with the SEC. The fund owned 39,958 shares of the company’s stock after buying an additional 31,331 shares during the quarter. Barclays PLC owned about 0.11% of FibroBiologics worth $123,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in FBLG. Fund Evaluation Group LLC purchased a new stake in FibroBiologics in the second quarter valued at about $5,265,000. State Street Corp raised its stake in shares of FibroBiologics by 26.5% in the third quarter. State Street Corp now owns 475,837 shares of the company’s stock worth $1,470,000 after purchasing an additional 99,789 shares during the last quarter. Bank of New York Mellon Corp purchased a new position in shares of FibroBiologics in the second quarter worth about $342,000. Symphony Financial Ltd. Co. purchased a new position in shares of FibroBiologics in the third quarter worth about $76,000. Finally, Rhumbline Advisers purchased a new position in shares of FibroBiologics in the second quarter worth about $115,000.

FibroBiologics Trading Down 8.8 %

Shares of FBLG stock opened at $2.06 on Thursday. FibroBiologics, Inc. has a twelve month low of $1.08 and a twelve month high of $55.00. The stock has a 50 day moving average of $2.54 and a 200 day moving average of $3.02.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on the company. Maxim Group assumed coverage on FibroBiologics in a research note on Tuesday, September 24th. They issued a “buy” rating and a $12.00 price objective for the company. D. Boral Capital restated a “buy” rating and issued a $16.00 price objective on shares of FibroBiologics in a research note on Friday, December 27th. Rodman & Renshaw assumed coverage on FibroBiologics in a research note on Thursday, December 12th. They issued a “buy” rating and a $12.00 price objective for the company. Finally, HC Wainwright reiterated a “buy” rating and set a $12.00 price target on shares of FibroBiologics in a research report on Wednesday, November 13th. Four research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $13.00.

About FibroBiologics

FibroBiologics, Inc operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer.